Actelion Pharmaceuticals Ltd

act-179811 - cadazolid

 

Study ID Status Type Title
AC-061-101 Completed Protocol Summary A Phase I, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics (including food interaction) of single ascending doses of ACT-179811 in healthy male subjects
AC-061-102 Completed Protocol Summary A Phase I, double-blind, placebo-controlled, randomized, multiple-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of ACT-179811 in healthy male subjects
AC-061-103 Completed Protocol Summary A Phase 1, open-label, single oral dose study to investigate the pharmacokinetics, safety, and tolerability of cadazolid in patients with severe Clostridium difficile infection (CDI)
AC-061A201 Completed Protocol Summary A multi-center, double-blind, randomized, active reference, parallel group study to evaluate the efficacy, safety and tolerability of a 10-day twice daily oral administration of three doses of cadazolid (ACT-179811) in subjects with Clostridium difficile associated diarrhea (CDAD)
AC-061A301 Completed Protocol Summary A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD)
AC-061A302 Completed Protocol Summary A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
AC-061A303 Terminated Protocol Summary A prospective, multicenter study to investigate the pharmacokinetics, safety, and efficacy of cadazolid versus vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea